Andrea Burgalassi

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Journal: Expert opinion on emerging drugs

Published: June 14, 2026

Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab.

Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab.

Journal: European journal of pharmacology

Published: April 08, 2026

Beyond symptom: Exploring the analgesic properties of vomiting in patients with migraine.

Beyond symptom: Exploring the analgesic properties of vomiting in patients with migraine.

Journal: Headache

Published: September 26, 2025

Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).

Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).

Journal: Therapeutic advances in neurological disorders

Published: June 25, 2025

Sex differences in the clinical features of 2,841 patients with migraine: a post-hoc, multicenter, cross-sectional study.

Sex differences in the clinical features of 2,841 patients with migraine: a post-hoc, multicenter, cross-sectional study.

Journal: Frontiers in neurology

Published: June 18, 2025

An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine.

An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine.

Journal: Cephalalgia : an international journal of headache

Published: December 10, 2024

Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.

Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.

Journal: Cephalalgia : an international journal of headache

Published: November 26, 2024

Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.

Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.

Journal: Cephalalgia : an international journal of headache

Published: November 05, 2024

Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.

Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.

Journal: Headache

Published: August 12, 2024

Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study.

Impact of duration of chronic migraine on long-term effectiveness of monoclonal antibodies targeting the calcitonin gene-related peptide pathway-A real-world study.

Journal: Headache

Published: February 02, 2024

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.

Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.

Journal: CNS drugs

Published: October 25, 2023

Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.

Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.

Journal: Cephalalgia : an international journal of headache

Published: March 15, 2023

Showing 1-12 of 14

Last Updated: 09/26/2026